Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bentlee Rundell

Nurse Practitioner, Family Fort Smith, AR Nurse Practitioner

NPI 1538649231 CMS profile 11063943

9101 Jenny Lind Rd, Fort Smith, AR 72908

Open in the dashboard

General payments

$9,943

639 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bentlee Rundell of Fort Smith, AR is reported in the CMS Open Payments database as having received $9,943 across 639 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,066 126
2024 General $1,871 105
2023 General $1,964 131
2022 General $2,200 143
2021 General $1,841 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bentlee Rundell
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Bentlee Rundell were reported at $2,066. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Bentlee Rundell Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,841 $124 $35–$379 $132
2022 $2,200 $141 $44–$430 $149
2023 $1,964 $154 $49–$476 $160
2024 $1,871 $165 $51–$504 $164
2025 $2,066 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,431 172 payments
  2. Novo Nordisk Inc $1,340 65 payments
  3. AstraZeneca Pharmaceuticals LP $818 33 payments
  4. Pfizer Inc. $715 67 payments
  5. GlaxoSmithKline, LLC. $697 51 payments
  6. Amgen Inc. $596 39 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $469 23 payments
  8. Lilly USA, LLC $406 33 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $287 18 payments
  10. Amarin Pharma Inc. $248 13 payments
  11. Other $1,937 125 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,846 636 payments
  2. Education $97 3 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $1,046 55 payments
  2. VRAYLAR $981 79 payments
  3. RYBELSUS $869 40 payments
  4. Ozempic $737 42 payments
  5. UBRELVY $607 45 payments
  6. TRELEGY ELLIPTA $582 42 payments
  7. FARXIGA $473 11 payments
  8. Kerendia $469 23 payments
  9. NURTEC ODT $452 48 payments
  10. ZAVZPRET $395 39 payments
  11. Other $6,534 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 106 drugs

Part D claims

4,194

Median for Nurse Practitioner: 389

Drug cost

$325,679

Median for Nurse Practitioner: $21,885

Branded share of claims

18.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 51 $79,241
Jardiance Empagliflozin Brand 23 $35,003
Ozempic Semaglutide Brand 17 $30,063
Trulicity Dulaglutide Brand 22 $27,218
Rexulti Brexpiprazole Brand 17 $26,805
Farxiga Dapagliflozin Propanediol Brand 23 $21,110
Myrbetriq Mirabegron Brand 15 $16,395
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $15,818
Eliquis Apixaban Brand 16 $15,327
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $9,779

The 10 drugs with the highest cost, of 106 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$28,049

Of which drugs: $1,666

Medicare patients

258

Average age 71

Services billed

977

151 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Chronic kidney disease 34%
Diabetes 29%
Ischemic heart disease 29%
Depression 27%
Osteoporosis 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 12 12 $982
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 80 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $328
$328 — —
VRAYLAR
  • AbbVie, Inc. $323
$323 — —
UBRELVY
  • AbbVie, Inc. $126
$126 — —
NURTEC ODT
  • PFIZER INC. $84
$84 — —
ZAVZPRET
  • PFIZER INC. $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

639 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record